Table 2.

Susceptibility of C. difficile isolates at baseline and at recurrence by treatment arm

	n	MIC (mg/L)	Ridinilazole	Vancomycin	Metronidazole	Fidaxomicin
Ridinilazole group vegetative isolates
day −1	44	MIC50	0.12	1	0.5	0.12
		MIC90	0.25	2	2	0.5
		range	0.06–0.5	1–4	0.12–4	0.06–1
recurrence	3	range	0.12–0.25	2–4	0.25–2	0.12–0.5
Vancomycin group vegetative isolates
day −1	45	MIC50	0.12	1	0.25	0.25
		MIC90	0.5	2	1	0.5
		range	0.06–0.5	0.5–2	0.12–2	0.06–1
recurrence	5	MIC50	0.12	1	0.25	0.25
		range	0.12–0.5	1–2	0.12–0.5	0.12–0.5